Profile data is unavailable for this security.
About the company
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.
- Revenue in USD (TTM)9.81m
- Net income in USD-47.73m
- Incorporated2000
- Employees48.00
- LocationCuris Inc128 Spring Street, 4 Maguire RoadLEXINGTON 02421United StatesUSA
- Phone+1 (617) 503-6500
- Fax+1 (617) 503-6501
- Websitehttps://www.curis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VolitionRX Ltd | 797.03k | -34.91m | 59.93m | 110.00 | -- | -- | -- | 75.19 | -0.4603 | -0.4603 | 0.0104 | -0.1901 | 0.0425 | -- | 6.32 | 7,245.73 | -188.25 | -111.92 | -- | -196.20 | -- | -- | -4,425.95 | -10,793.31 | -- | -173.85 | -- | -- | 153.04 | -- | -16.68 | -- | 29.13 | -- |
| Kronos Bio Inc | 7.59m | -116.39m | 60.09m | 61.00 | -- | 0.4387 | -- | 7.92 | -2.00 | -2.00 | 0.1301 | 2.28 | 0.0322 | -- | -- | 122,371.00 | -49.32 | -35.47 | -54.43 | -37.14 | -- | -- | -1,534.11 | -7,975.76 | -- | -- | 0.00 | -- | -- | -- | 15.41 | -- | -8.78 | -- |
| Bakhu Holdings Corp | 0.00 | -1.92m | 60.26m | 2.00 | -- | -- | -- | -- | -0.0064 | -0.0064 | 0.00 | -0.0325 | 0.00 | -- | -- | 0.00 | -281.75 | -4,391.82 | -- | -- | -- | -- | -- | -- | -- | -8.39 | -- | -- | -- | -- | 33.37 | -- | -- | -- |
| Reneo Pharmaceuticals Inc | 0.00 | -70.71m | 61.16m | 8.00 | -- | 0.7528 | -- | -- | -2.17 | -2.17 | 0.00 | 2.43 | 0.00 | -- | -- | 0.00 | -77.06 | -- | -83.08 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.95 | -- | -- | -- |
| Protara Therapeutics Inc | 0.00 | -42.47m | 61.56m | 26.00 | -- | 0.5853 | -- | -- | -3.74 | -3.74 | 0.00 | 5.11 | 0.00 | -- | -- | 0.00 | -48.67 | -37.02 | -52.23 | -38.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 38.71 | -- | -17.67 | -- |
| RetinalGenix Technologies Inc | 0.00 | -2.09m | 62.25m | 0.00 | -- | -- | -- | -- | -0.1205 | -0.1205 | 0.00 | -0.0797 | 0.00 | -- | -- | -- | -929,284.40 | -9,163.75 | -- | -- | -- | -- | -- | -- | -- | -543.50 | -- | -- | -- | -- | 46.58 | -- | -- | -- |
| Avrobio Inc | 0.00 | 30.31m | 62.85m | 13.00 | 2.03 | 0.7073 | 2.05 | -- | 0.6903 | 0.6903 | 0.00 | 1.98 | 0.00 | -- | -- | 0.00 | 34.57 | -45.22 | 38.47 | -49.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
| Turnstone Biologics Corp | 0.00 | -74.92m | 62.91m | 82.00 | -- | 0.7863 | -- | -- | -3.53 | -3.53 | 0.00 | 3.46 | 0.00 | -- | -- | 0.00 | -80.25 | -- | -94.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -73.66 | -- | -78.05 | -- | -- | -- |
| AN2 Therapeutics Inc | 0.00 | -66.03m | 63.24m | 41.00 | -- | 0.5715 | -- | -- | -2.59 | -2.59 | 0.00 | 3.71 | 0.00 | -- | -- | 0.00 | -62.19 | -- | -68.38 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.33 | -- | -- | -- |
| Champions Oncology Inc | 49.22m | -9.73m | 63.62m | 230.00 | -- | -- | -- | 1.29 | -0.7183 | -0.7183 | 3.64 | -0.1514 | 1.56 | -- | 6.17 | 214,017.40 | -30.91 | -5.40 | -96.45 | -11.88 | 40.09 | 47.96 | -19.76 | -3.09 | -- | -- | -- | -- | 9.69 | 21.63 | -1,073.54 | -- | 18.50 | -- |
| Curis Inc | 9.81m | -47.73m | 63.77m | 48.00 | -- | 6.74 | -- | 6.50 | -8.68 | -8.68 | 1.77 | 1.61 | 0.1253 | -- | 4.39 | 204,416.70 | -60.97 | -37.25 | -69.58 | -41.12 | 97.60 | 96.05 | -486.45 | -409.44 | -- | -- | 0.00 | -- | -1.37 | -0.7891 | 16.34 | -- | -- | -- |
| Mural Oncology PLC | 0.00 | -191.90m | 63.80m | 117.00 | -- | 0.2716 | -- | -- | -11.49 | -11.49 | 0.00 | 13.88 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.29 | -- | -- | -- |
| Bioqual Inc | 62.86m | 957.02k | 64.85m | 108.00 | 67.76 | 1.67 | 18.49 | 1.03 | 1.07 | 1.07 | 70.28 | 43.41 | 1.04 | -- | 2.99 | -- | 1.59 | 8.14 | 1.80 | 9.52 | 14.13 | 19.36 | 1.52 | 7.13 | -- | -- | 0.00 | 21.43 | -5.27 | 11.79 | -84.12 | -25.26 | 1.60 | 10.76 |
| Ikena Oncology Inc | 3.85m | -70.09m | 65.15m | 34.00 | -- | 0.4194 | -- | 16.93 | -1.58 | -1.58 | 0.0861 | 3.22 | 0.0237 | -- | -- | 89,488.38 | -43.11 | -29.72 | -46.56 | -34.62 | -- | -- | -1,821.54 | -294.90 | -- | -- | 0.00 | -- | -41.35 | 56.05 | 0.8711 | -- | 6.30 | -- |
| enVVeno Medical Corp | 0.00 | -22.12m | 65.98m | 31.00 | -- | 1.56 | -- | -- | -1.70 | -1.70 | 0.00 | 3.18 | 0.00 | -- | -- | 0.00 | -54.31 | -58.43 | -56.14 | -62.76 | -- | -- | -- | -260,799.30 | -- | -- | 0.00 | -- | -- | -- | 4.67 | -- | 21.58 | -- |
| Checkpoint Therapeutics Inc | 68.00k | -52.32m | 68.17m | 23.00 | -- | -- | -- | 1,002.54 | -2.37 | -2.37 | 0.0028 | -0.2872 | 0.0076 | -- | -- | 2,956.52 | -585.51 | -142.43 | -- | -342.79 | -- | -- | -76,938.23 | -6,554.97 | -- | -- | -- | -- | -46.35 | -50.61 | 17.21 | -- | -- | -- |
Data as of May 22 2024. Currency figures normalised to Curis Inc's reporting currency: US Dollar USD
34.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Maverick Capital Ltd.as of 31 Mar 2024 | 582.27k | 9.88% |
| M28 Capital Management LPas of 31 Mar 2024 | 421.95k | 7.16% |
| Kingdon Capital Management LLCas of 04 Apr 2024 | 345.73k | 5.87% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 217.03k | 3.68% |
| CM Management LLCas of 31 Mar 2024 | 120.00k | 2.04% |
| Citigroup Global Markets, Inc. (Investment Management)as of 31 Mar 2024 | 91.87k | 1.56% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 91.56k | 1.55% |
| Geode Capital Management LLCas of 31 Mar 2024 | 62.30k | 1.06% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 53.48k | 0.91% |
| Focused Wealth Management, Inc.as of 31 Mar 2024 | 33.16k | 0.56% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
